BCL2L1 and melanoma: For instance, it has been shown that Sorafenib down-modulates the levels of Bcl-2 and Bcl-XL, and such down-modulation was shown to be MAPK-independent in A2058 and SKMEL5 melanoma cells but not in A375 cells [41].